AR057327A1 - Compuestos de benzimidazol-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas - Google Patents
Compuestos de benzimidazol-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR057327A1 AR057327A1 ARP060102166A ARP060102166A AR057327A1 AR 057327 A1 AR057327 A1 AR 057327A1 AR P060102166 A ARP060102166 A AR P060102166A AR P060102166 A ARP060102166 A AR P060102166A AR 057327 A1 AR057327 A1 AR 057327A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- ochf2
- ocf3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones farmacéuticas que comprenden dichos compuestos, métodos para utilizar dichos compuestos para tratar enfermedades asociadas con la actividad del receptor 5HT4, y procesos e intermediarios utiles para preparar dichos compuestos. Formas cristalinas de un compuestos de formula (1). Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), donde: R1 es alquilo C3-5, opcionalmente sustituido con -OH; y X se selecciona entre: a) -C(O)OR2, donde R2 es alquilo C1-4 o -(CH2)n-fenilo donde n es 0 o 1; b) -C(O)R3, donde R3 se selecciona entre: fenilo opcionalmente sustituido con 1, 2, o 3 sustituyentes seleccionados entre alquilo C1-4, halo, alcoxi C1-4, -CF3, -OCF3, -OCHF2, y -CN; alquilo C1-5; cicloalquilo C4- 5; y -(CH2)m-A, donde m es 0 o 1 y A se selecciona entre amino, furanilo, tiofenilo, morfolinilo, tetrahidrofuranilo, piridinilo, naftalenilo, pirrolilo, tiomorfolinilo, pirrolidinilo, piperidinilo, oxoazetidinilo, tiazolidinilo, 1,1-dioxo isotiazolidinilo, y 2,4-dimetilisoxazolilo; c) -C(O)NR4R5, donde R4 es hidrogeno o alquilo C1-3, y R5 es fenilo opcionalmente sustituido con 1, 2, o 3 sustituyentes seleccionados entre alquilo C1-4, halo, alcoxi C1-4, -CF3, -OCF3, y -OCHF2; d) - C(O)C(R6R7)R8, donde R6 es hidrogeno o alquilo C1-3 y R7 es hidrogeno, -OH, o alquilo C1-3; o R6 y R7 juntos forman oxo o -(CH2)2-; y R8 es fenilo o ciclohexilo, donde fenilo o ciclohexilo están opcionalmente sustituidos con 1, 2, o 3 sustituyentes seleccionados entre alquilo C1-4, halo, alcoxi C1-4, -CF3, -OCF3, -OCHF2, y -CN; e) -C(O)C(HR9)OR10, donde R9 es hidrogeno o alquilo C1-3, y R10 es fenilo opcionalmente sustituido con 1, 2, o 3 sustituyentes seleccionados entre alquilo C1-4, halo, alcoxi C1-4, -CF3, -OCF3, y -OCHF2; y f) -S(O)2R11, donde R11 se selecciona entre alquilo C1-3, -CH2-fenilo, furanilo, tiofenilo, morfolinilo, tetrahidrofuranilo, piridinilo, naftalenilo, pirrolilo, tiomorfolinilo, pirrolidinilo, piperidinilo, oxoazetidinilo, tiazolidinilo, 1,1-dioxo isotiazolidinilo, 2,4-dimetilisoxazolilo, y fenilo opcionalmente sustituido con 1, 2, o 3 sustituyentes seleccionados entre alquilo C1-4, halo, alcoxi C1-4, -CF3, -OCF3, -OCHF2, y -CN; o una sal, un solvato o un estereoisomero aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68446605P | 2005-05-25 | 2005-05-25 | |
| US68447805P | 2005-05-25 | 2005-05-25 | |
| US74841505P | 2005-12-08 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057327A1 true AR057327A1 (es) | 2007-11-28 |
Family
ID=37452788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102166A AR057327A1 (es) | 2005-05-25 | 2006-05-24 | Compuestos de benzimidazol-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8143279B2 (es) |
| EP (1) | EP1899324B1 (es) |
| JP (2) | JP5072111B2 (es) |
| KR (1) | KR101333280B1 (es) |
| AR (1) | AR057327A1 (es) |
| AT (1) | ATE535523T1 (es) |
| AU (1) | AU2006250009B2 (es) |
| BR (1) | BRPI0611202C1 (es) |
| CA (1) | CA2607280C (es) |
| CY (1) | CY1112366T1 (es) |
| DK (1) | DK1899324T3 (es) |
| EA (1) | EA013240B1 (es) |
| ES (1) | ES2376115T3 (es) |
| HK (1) | HK1110980A1 (es) |
| HR (1) | HRP20120108T2 (es) |
| IL (1) | IL186883A (es) |
| MA (1) | MA29541B1 (es) |
| MX (1) | MX2007014762A (es) |
| MY (1) | MY147756A (es) |
| NO (1) | NO339658B1 (es) |
| NZ (1) | NZ563068A (es) |
| PE (1) | PE20061446A1 (es) |
| PL (1) | PL1899324T3 (es) |
| PT (1) | PT1899324E (es) |
| SI (1) | SI1899324T1 (es) |
| TW (1) | TWI388555B (es) |
| WO (1) | WO2006127815A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1664036T3 (da) * | 2003-09-03 | 2012-02-13 | Pfizer | Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7256294B2 (en) * | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2410857B1 (en) | 2009-03-23 | 2014-01-29 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| PT2419104T (pt) * | 2009-04-13 | 2018-01-31 | Theravance Biopharma R&D Ip Llc | Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US9676703B2 (en) | 2013-08-09 | 2017-06-13 | Santen Pharmaceutical Co., Ltd. | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| JPH111472A (ja) | 1996-04-30 | 1999-01-06 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体及びそれを含有する医薬組成物 |
| SK15852000A3 (sk) * | 1998-04-28 | 2001-06-11 | Dainippon Pharmaceutical Co., Ltd. | Derivát 1-[(1-substituovaného-4-piperidinyl)metyl]-4-piperidínu, spôsob jeho prípravy, farmaceutický prípravok obsahujúci tento derivát a medziprodukt tohto derivátu |
| WO2000026192A1 (de) | 1998-11-03 | 2000-05-11 | Basf Aktiengesellschaft | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
| JP2001122784A (ja) | 1999-10-27 | 2001-05-08 | Dainippon Pharmaceut Co Ltd | １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬 |
| CA2410939C (en) * | 2000-06-07 | 2010-02-16 | Aryx Therapeutics | Materials and methods for the treatment of gastroesophageal reflux disease |
| US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| US7384934B2 (en) | 2002-08-05 | 2008-06-10 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines |
| MXPA05003065A (es) * | 2002-09-20 | 2005-05-27 | Pfizer | Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4. |
| JP2004277318A (ja) * | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物 |
| JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
| JP2004277320A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物 |
| DK1664036T3 (da) | 2003-09-03 | 2012-02-13 | Pfizer | Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning |
| US7256294B2 (en) | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2006
- 2006-05-17 MY MYPI20062263A patent/MY147756A/en unknown
- 2006-05-22 TW TW095118168A patent/TWI388555B/zh not_active IP Right Cessation
- 2006-05-23 PE PE2006000543A patent/PE20061446A1/es active IP Right Grant
- 2006-05-24 JP JP2008513672A patent/JP5072111B2/ja not_active Expired - Fee Related
- 2006-05-24 NZ NZ563068A patent/NZ563068A/en not_active IP Right Cessation
- 2006-05-24 US US11/920,817 patent/US8143279B2/en not_active Expired - Fee Related
- 2006-05-24 AU AU2006250009A patent/AU2006250009B2/en not_active Ceased
- 2006-05-24 WO PCT/US2006/020085 patent/WO2006127815A2/en active Application Filing
- 2006-05-24 PL PL06760341T patent/PL1899324T3/pl unknown
- 2006-05-24 AR ARP060102166A patent/AR057327A1/es active IP Right Grant
- 2006-05-24 SI SI200631257T patent/SI1899324T1/sl unknown
- 2006-05-24 BR BRPI0611202A patent/BRPI0611202C1/pt not_active IP Right Cessation
- 2006-05-24 CA CA2607280A patent/CA2607280C/en active Active
- 2006-05-24 KR KR1020077030010A patent/KR101333280B1/ko active IP Right Grant
- 2006-05-24 AT AT06760341T patent/ATE535523T1/de active
- 2006-05-24 PT PT06760341T patent/PT1899324E/pt unknown
- 2006-05-24 EP EP06760341A patent/EP1899324B1/en active Active
- 2006-05-24 US US11/439,671 patent/US7759363B2/en active Active
- 2006-05-24 DK DK06760341.5T patent/DK1899324T3/da active
- 2006-05-24 ES ES06760341T patent/ES2376115T3/es active Active
- 2006-05-24 EA EA200702612A patent/EA013240B1/ru not_active IP Right Cessation
- 2006-05-24 MX MX2007014762A patent/MX2007014762A/es active IP Right Grant
-
2007
- 2007-10-24 IL IL186883A patent/IL186883A/en active IP Right Grant
- 2007-12-10 MA MA30466A patent/MA29541B1/fr unknown
- 2007-12-17 NO NO20076481A patent/NO339658B1/no not_active IP Right Cessation
-
2008
- 2008-05-19 HK HK08105518.4A patent/HK1110980A1/xx not_active IP Right Cessation
-
2010
- 2010-06-09 US US12/796,902 patent/US8377964B2/en active Active
-
2012
- 2012-02-01 HR HR20120108T patent/HRP20120108T2/hr unknown
- 2012-02-17 CY CY20121100168T patent/CY1112366T1/el unknown
- 2012-07-23 JP JP2012162692A patent/JP2012197322A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,783 patent/US20130273568A1/en not_active Abandoned
-
2014
- 2014-09-17 US US14/488,520 patent/US9428489B2/en not_active Expired - Fee Related
-
2016
- 2016-07-28 US US15/221,841 patent/US9975877B2/en active Active
-
2018
- 2018-04-19 US US15/956,958 patent/US10233172B2/en active Active
-
2019
- 2019-01-29 US US16/260,984 patent/US10696656B2/en not_active Expired - Fee Related
-
2020
- 2020-05-22 US US16/881,209 patent/US11254655B2/en active Active
-
2022
- 2022-01-12 US US17/573,814 patent/US20220274957A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057327A1 (es) | Compuestos de benzimidazol-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas | |
| AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
| NO20083435L (no) | Formuleringer | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| TW200722086A (en) | Compounds comprising an oxazole or thiazole moiety, processes for making them and their uses | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR060945A1 (es) | Prolinamidas sustituidas y su uso como medicamentos | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| AR086958A1 (es) | Antagonistas de trpv4 | |
| JO2935B1 (en) | 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine) | |
| AR050407A1 (es) | Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| CO6150179A2 (es) | Derivados de n-(amino-heteroaril)-1h-hindol-2-carboxamidas su preparacion y su aplicacion en terapeutica | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| PE20091974A1 (es) | Derivados de indazoles sustituidos con fenil o piridinilo | |
| AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| AR057034A1 (es) | Metodos para purificar tigeciclina | |
| AR044715A1 (es) | Compuestos tipo amidas que inhiben la reabsorcion de las monoaminas | |
| PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| GB0517191D0 (en) | Compounds | |
| CO5650235A2 (es) | Derivados de imidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |